Life SciencesLiability
Contact

TL;DR

Life sciences insurance is the specialty program built around regulatory, contractual, and product-risk exposures unique to companies that develop, manufacture, test, distribute, or dispense pharmaceutical drugs, biologics, medical devices, diagnostic tests, or compounded therapeutics. Coverage lines size to FDA-class product exposure (not generic class codes), contracts drive specific endorsement schedules generalist programs miss, and the carrier panel is a narrow specialty set. This guide covers the 12 coverage lines, the differences by vertical, the shifts by stage, the gaps generalist brokers miss, and what to ask a specialty broker before signing.

Complete coverage guide

Life sciences insurance: the complete coverage guide.

Life sciences insurance is the specialty insurance program built around the regulatory, contractual, and product-risk exposures unique to companies that develop, manufacture, test, distribute, or dispense pharmaceutical drugs, biologics, medical devices, diagnostic tests, or compounded therapeutics. It differs from generic commercial insurance in three structural ways: the coverage lines are sized to FDA-class product exposure rather than generic class codes; the contractual requirements (sponsor MSAs, GPO supplier agreements, PBM credentialing, hospital purchase contracts, clinical trial agreements, 503B outsourcing agreements) drive specific endorsement schedules generalist policies don\'t address; and the underwriting carriers active in the class are a narrow specialty set, not the broader admitted commercial market.

This guide covers: the twelve coverage lines a life sciences company actually needs, how those needs differ by company type (biotech, medical device, CDMO, CRO, compounding pharmacy, 503B, GLP-1 compounder, diagnostic lab), how they shift across company stage (pre-revenue → clinical → commercial → M&A), the seven most common gaps generalist brokers miss, and what to ask a specialty broker before signing. Educational only - coverage availability and pricing vary by carrier, state, operator size, product mix, and risk profile. Buyers should consult licensed counsel and a qualified specialty insurance broker for binding decisions.

Run the Free Insurance Requirements AnalyzerFree Coverage Review

Coverage lines

The twelve coverage lines a life sciences company needs.

Most operators carry a subset of these depending on company type, stage, and contractual obligations. Few operators need every line; almost no operators need fewer than five.

Coverage
Who needs it
Typical limits
What triggers it
Commercial General Liability (CGL)
Every life sciences company - baseline.
$1M per occurrence / $2M aggregate; $2M+ products/completed-ops aggregate.
Third-party bodily injury or property damage at your premises or arising from operations.
Products Liability
CDMOs, 503Bs, medical device manufacturers, generic pharma, supplement and OTC makers - anyone producing a physical product that enters commerce.
$5M-$10M per occurrence; $10M-$25M aggregate baseline. Implantable devices and high-risk drug classes scale to $25M+.
Bodily injury or property damage caused by a defective product. Recall events, adverse events, class-action filings downstream.
Clinical Trial Liability (CTL)
Sponsors, CROs, investigator-initiated study programs - anyone running interventions on human subjects.
$5M-$10M per trial baseline; first-in-human dosing of irreversible interventions can scale to $25M+.
Subject injury or death arising from a clinical trial. Site indemnification flows through CTL, not CGL.
Professional Liability / Errors & Omissions (E&O)
CROs, CDMOs with development services, regulatory consultants, contract laboratories, bioanalytical services, digital health and AI healthtech.
$1M-$5M claims-made; $5M-$10M for larger development organizations.
Pure economic loss from negligent performance of professional services (failed batch from formulation error, missed analytical qualification, breached protocol, faulty study report).
Cyber Liability + HIPAA Breach Response
Every life sciences company handling PHI, sponsor-confidential data, drug master files, or operating EHR/portal integrations - effectively all of them in 2026.
$1M-$5M for mid-market; $5M-$10M for sponsor-data-heavy or PHI-heavy operations.
Data breach, ransomware, business interruption from a cyber event, HIPAA breach notification obligations, state-law privacy claims (CCPA, MHMDA, BIPA, CTDPA, MPIPA, CMIA).
Directors & Officers (D&O)
VC-backed clinical-stage biotech, IPO/SPAC-bound operators, post-IPO public companies, M&A-active CDMOs and 503Bs.
$1M-$5M private company D&O baseline; $10M-$50M for clinical-stage public biotech; transactional D&O sized to offering.
Securities class actions, derivative suits, regulatory enforcement against directors and officers personally. Required by virtually every institutional investor at term sheet.
Product Recall Coverage
Medical device manufacturers (especially Class II/III), pharmaceutical manufacturers, 503B outsourcing facilities, supplement and OTC makers.
$1M-$5M standalone recall policy with explicit FDA Class I/II/III coverage.
FDA-mandated or voluntary recall - withdrawal expense, notification, transportation, destruction, replacement supply, lost gross profit.
Property + Equipment
Manufacturers (CDMOs, 503Bs, medical device), labs (CRO, diagnostic), biotech with lab space.
Replacement-cost basis on building, equipment, in-process inventory. cGMP-aligned property forms with validation loss endorsement for regulated manufacturing.
Fire, flood, equipment breakdown, cleanroom contamination, validation losses on bioreactor or sterile-suite campaigns.
Workers Compensation + Employers Liability
Every employer. State-mandated.
Statutory workers comp + $1M employers liability. Texas non-subscriber arrangements have specific structural alternatives.
Employee injury arising from employment. Lab safety and clinical exposures drive class-code selection.
Employment Practices Liability (EPLI)
Companies with employees - typically structural once headcount exceeds 10-15.
$1M-$5M claims-made.
Discrimination, harassment, wrongful termination, retaliation, wage-and-hour claims.
Cargo / Warehouseman's Legal Liability
CDMOs handling sponsor-supplied API, 503Bs shipping compounded preparations, medical device shippers, anyone moving biologics or temperature-sensitive product.
$500K-$5M per shipment depending on product value and route risk.
Damage or loss of customer-owned property in your custody or in transit.
Contractual Review (MSA, GPO, PBM, CTA, 503B agreements)
Every operator under any commercial contract with insurance schedule attached - effectively all life sciences operators with B2B customers.
Not a coverage line - a service component. Specialty brokers include schedule review and gap analysis as part of placement.
Sponsor MSA, GPO supplier agreement, PBM credentialing packet, hospital purchase contract, clinical trial agreement, 503B outsourcing agreement - each lands with an insurance schedule the operator's current program may or may not satisfy.

By company type

The coverage mix shifts materially by sub-vertical.

A pre-revenue clinical-stage biotech and a 503B outsourcing facility both fall under "life sciences," but the insurance programs share almost no overlap in priority or structure. The dominant coverage line and the dominant contractual driver differ for each sub-vertical:

CDMO Insurance (Pharma & Medical Device Contract Manufacturers)

Products liability ($5M-$10M), professional liability for cGMP work, sponsor MSA compliance, cargo for sponsor-supplied API, cyber for drug master file data.

Practice page

CRO Insurance (Contract Research Organizations)

Clinical trial liability, professional liability, cyber sized to PHI volume, sponsor MSA indemnification coordination.

Practice page

Medical Device Insurance (Class I/II/III Manufacturers)

Products liability tower (often $25M+ for implantables), MDR liability extension, GPO supplier compliance, cyber for connected devices.

Practice page

Biotech Insurance (Clinical-Stage Drug Companies)

D&O architecture (private then IPO/SPAC transactional), clinical trial liability with site additional insureds, employment practices, fiduciary, cyber, IP infringement.

Practice page

Compounding Pharmacy Insurance (503A Sterile/Non-Sterile)

Druggist professional liability, USP 797/800 compliance documentation, products liability, PBM credentialing requirements, GLP-1 carrier exclusion landscape.

Practice page

503B Outsourcing Facility Insurance

Hospital purchase contract insurance compliance, Joint Commission MCC certification, cGMP property with validation loss endorsement, FDA recall extension, Vizient/Premier/HealthTrust schedules.

Practice page

GLP-1 Compounding Insurance

Products liability carrier exclusion review at renewal, market-mapping to carriers still writing the exposure, FDA enforcement risk.

Practice page

Diagnostic Lab Insurance (CLIA Clinical & Molecular)

Professional liability / E&O, cyber/HIPAA sized to PHI volume, bioanalytical method liability, hospital reference laboratory contracts.

Practice page

Clinical Trial Insurance (Sponsors, CROs, Investigators)

Per-trial clinical trial liability sized by phase / sites / enrollment / geography, EU CTR compliance for EU sites, sponsor-CRO indemnity boundary, investigator-sponsored trial coordination with AMC self-insurance.

Practice page

By company stage

Insurance priorities shift across the lifecycle.

A pre-revenue biotech and a commercial-stage operator face different coverage triggers and different investor or counterparty demands. The structural shift is roughly:

Pre-revenue / pre-clinical

D&O (mandatory once VC funded), basic CGL, workers comp, cyber. Skip products liability and CTL until materially relevant. Property scoped to lab space.

Clinical-stage

Add clinical trial liability ahead of first-in-human dosing. D&O scales with funding round and pipeline disclosure cadence. Cyber scales with PHI and IND data volume. Professional liability if you offer development services to other sponsors.

Pre-commercial / launch

Add products liability ahead of commercial launch - sized to expected first-year revenue and product class. Add recall coverage as standalone. Scale D&O for transactional events (IPO, SPAC, partnership). Review all sponsor and hospital contracts in pipeline against schedule.

Commercial-stage

Products liability tower at full deployment scale. D&O at public-company sizing (Side A + Side B/C). Cyber at enterprise scale. Recall coverage with explicit FDA Class I/II/III. Employment practices liability scales with headcount.

M&A-active or transactional

Reps & warranties insurance for transactions. Runoff/tail D&O for acquired entities. Transaction-specific cyber and IP diligence. Sponsor and supplier contract assignment review.

Contractual triggers

Six contracts that drive most insurance schedule demands.

The single biggest source of insurance program friction in life sciences is a contract landing with an insurance schedule the operator\'s current program doesn\'t satisfy. The six contract types that most commonly trigger a rebuild:

  1. Sponsor Master Service Agreement (MSA) - drives CDMO and CRO insurance schedules. Typically demands products liability, additional-insured wording, primary/non-contributory, waiver of subrogation, 30-day notice of cancellation, sometimes professional liability for development scope.
  2. GPO Supplier Agreement (Vizient, Premier, HealthTrust) - drives medical device and 503B insurance schedules. Standardized templates enforced through Symplr/Reptrax credentialing platforms.
  3. Hospital Purchase Contract - direct (non-GPO) hospital purchasing agreements with IDNs and academic medical centers. Insurance schedules inherit from GPO templates but with hospital- specific customizations.
  4. PBM Credentialing Packet (Express Scripts, CVS Caremark, OptumRx) - drives 503A and 503B pharmacy network credentialing. Druggist professional liability and general liability minimums plus current COI on file.
  5. Clinical Trial Agreement (CTA) - drives biotech sponsor and CRO insurance schedules. Typically demands clinical trial liability with site and investigator additional-insured wording.
  6. 503B Outsourcing Agreement - direct supply contracts between 503B outsourcing facilities and hospital pharmacies. cGMP-aligned property, FDA recall extension, Joint Commission MCC attestation.

Our free Insurance Requirements Analyzer translates the insurance section of any of these six contracts into plain English with negotiability notes, and flags gaps against the operator\'s current program. A specialist returns a clause-by-clause review within one business day.

Common gaps

Seven gaps generalist brokers miss.

Most life sciences operators placed by generalist commercial brokers have at least one structural gap their current COI doesn\'t reveal. The seven that recur most often:

CMO scope-creeps into CDMO development work without adding professional liability/E&O.

Impact:A failed development batch produces pure economic loss; products liability excludes it; uninsured indemnity owed to sponsor falls on the balance sheet.

503B passes credentialing with CG 20 10 (ongoing-ops AI) but not CG 20 37 (products/completed-ops AI).

Impact:Hospital orders fail to ship via Symplr/Reptrax credentialing platform until the second endorsement is added.

Compounding pharmacy renewal endorsement schedule adds GLP-1 exclusion without prominent disclosure.

Impact:Products liability for GLP-1 revenue line is uninsured; carrier denies if claim hits; uncovered exposure on a high-revenue product.

Clinical-stage biotech renews D&O without addressing pre-IPO transactional gap.

Impact:Post-IPO stock-drop securities class action surfaces gap between renewal D&O and transactional D&O; coverage fight at the worst possible moment.

Medical device manufacturer carries products liability on claims-made form instead of occurrence form.

Impact:Long claim tail on implantables (often 10-20 years between manufacture and claim) exceeds claims-made coverage window; uncovered legacy product exposure.

CRO carries cyber at $1M for a sponsor portfolio with multi-million-PHI-record studies.

Impact:Single breach incident exhausts the cyber limit before notification expense is paid; sponsor indemnity comes out of pocket.

Generalist broker places life-sciences operator in standard manufacturer products policy without recall extension.

Impact:First Class II FDA recall reveals sublimited or absent recall coverage; uncovered recall costs run into millions.

What to ask a specialty broker

Eight questions before you bind.

  1. How many life sciences operators are you currently placing programs for in my sub-vertical?
  2. Which specialty markets are you accessing for products liability - admitted, surplus lines via wholesale, or both?
  3. Can you provide a sample sponsor MSA, GPO supplier agreement, or hospital purchase contract you\'ve walked a similar operator through, with the schedule gaps and resolutions documented?
  4. What\'s your process for reviewing my actual contracts in pipeline (not just my current COI) against carrier policy forms before binding?
  5. How do you handle the recall coverage question - embedded sublimit, standalone policy, or layered structure?
  6. Does your placement include professional liability/E&O as a standalone line, or is it bundled inside the CGL/products policy?
  7. What\'s the carrier appetite picture for my class right now - specifically for {GLP-1 / cGMP property / connected device cyber / IPO transactional D&O / etc.} - and how has it shifted in the last 12 months?
  8. What\'s your response SLA on a contract review or coverage question? (We commit to end of business day.)

Why specialty matters

Generalist brokers place life sciences operators on the wrong forms.

The most common failure mode in life sciences insurance is a generalist commercial broker placing an operator on a standard manufacturer or service-firm policy form. The COI looks compliant. The limits look right. The premium is competitive. Everything fails at first claim - products liability that excluded recall extensions, additional-insured wording that didn\'t cover products/completed operations, cyber that sublimited HIPAA breach response, professional liability missing because the operator was placed as a manufacturer.

The specialty market for life sciences insurance is narrow. A small number of carriers - both admitted and surplus-lines - actively underwrite the class with familiarity for cGMP, USP 797/800, FDA recall structures, clinical trial liability for first-in-human dosing, D&O for clinical-stage public biotech, hospital purchase contract insurance schedules, GPO supplier compliance, MDR liability extensions, and the rest of the specialized coverage forms life sciences operators actually need.

We do not name specific carriers on this site (Texas Department of Insurance advertising-rule compliance + agency-neutral positioning). What we can do is rebuild your program around the actual contract requirement, place it through carriers with documented life sciences appetite, and review every commercial contract in your pipeline against your bound program before you sign.

Resources on this site

Where to go deeper.

CDMO Insurance practice page - sponsor MSA insurance, products tower sizing, recall coverage

CRO Insurance practice page - clinical trial liability, professional liability, cyber for PHI

Medical Device Insurance practice page - GPO supplier compliance, MDR liability, connected device cyber

Biotech Insurance practice page - D&O for clinical-stage, CTA insurance schedules

Compounding Pharmacy practice page - druggist professional liability, USP 797/800

503B Outsourcing practice page - hospital purchase contract compliance, cGMP property

GLP-1 Compounding practice page - 2026 carrier exclusion landscape, re-papering

Diagnostic Lab practice page - CLIA labs, bioanalytical, hospital reference

Cost Guide - typical premium ranges by sub-vertical and revenue band

Clause Glossary - 49 hand-translated insurance clauses

Q&A Library - 23 long-form answers with primary-source citations

Insights blog - MSA requirements, recall, GLP-1, USP 797/800, 503B field guide

Clinical trial insurance guide - sponsor-side CTL by phase, EU CTR placement, sponsor-CRO boundary

Best cyber insurance for CROs 2026 - five cyber program structures for clinical and pre-clinical CROs

Biotech cyber insurance - five tower structures by funding stage

503A vs 503B insurance comparison - clause-by-clause coverage differences

How to evaluate a sponsor MSA insurance section - Q&A

AI drug discovery startup insurance - Q&A

Digital health / AI healthtech pre-fundraise insurance - Q&A

CLIA clinical laboratory insurance requirements - Q&A

Foreign voluntary workers comp for life sciences - Q&A

Texas LLC structure for life sciences operators - Q&A

Frequently asked

Common questions about life sciences insurance

How many coverage lines does a life sciences company actually need?

Most operators need 8-12 distinct coverage lines: commercial general liability, products liability, professional liability/E&O, D&O, EPLI, cyber, property with cGMP validation extension, commercial auto, workers compensation, environmental (for hazardous-drug or lab operations), fiduciary, and crime. The exact mix depends on company type and stage - a pre-clinical CRO does not need products liability; a 503B does not need fiduciary at scale. The MSA Decoder maps your specific contracts to the lines that matter.

How does life sciences insurance differ from generic commercial insurance?

Three structural differences: coverage lines are sized to FDA-class product exposure rather than generic class codes; contractual requirements (sponsor MSAs, GPO supplier agreements, PBM credentialing, hospital purchase contracts, CTAs, 503B agreements) drive specific endorsement schedules that generalist policies do not address; and the underwriting carriers active in the class are a narrow specialty set, not the broader admitted commercial market.

What is the biggest gap generalist brokers miss?

The single most common gap is products + completed operations additional insured wording. Generalist programs default to AI for ongoing operations only, which does not respond after the product leaves the manufacturer's control - the highest-risk window. Sponsor MSAs and hospital purchase contracts almost universally require blanket AI for products and completed operations on a primary, non-contributory basis (CG 20 10 + CG 20 37). The COI may say "additional insured" but the underlying endorsement is wrong.

When does a life sciences company need to switch from generalist to specialty insurance?

At the first sponsor MSA, GPO supplier agreement, hospital purchase contract, or clinical trial agreement that has its own insurance schedule. Most generalist programs satisfy 30-60% of that schedule on strict reading. The structural fix is rebuilding the program on a base form designed for the regulatory and contractual environment, not on a generic light-manufacturing or professional-services template. The MSA Decoder shows the specific gaps in 12 minutes.

How does the program shift across company stage?

Pre-revenue clinical-stage operators focus on D&O, CTL, cyber, and IP/E&O. Commercial-launch operators add products liability tower scaled to commercial distribution, recall coverage, and contingent business interruption. M&A-prepped operators add representations and warranties coverage and ensure tail/run-off coverage on all claims-made policies. The transitions are the highest-risk moments because operators tend to keep the prior structure when the exposure profile has materially shifted.

What should you ask a specialty broker before signing?

Five questions: (1) Which carriers in your panel actively underwrite my specific vertical and stage? (2) How will the program respond to my specific sponsor MSA insurance schedule? (3) What endorsements have you added to address gaps the generalist program left? (4) What is the renewal calendar and how does it align with my sponsor contract events? (5) When a claim hits, who is the claims contact and what is the response SLA? A specialty broker should answer all five clearly without deferring to a carrier rep.

Next steps

Keep going.

Why operators choose this practice

  • Life sciences only

    Every placement passes through specialty life-sciences underwriters - not a general manufacturer or healthcare desk.

  • All 50 US states

    Programs placed nationally with deep practice content for the 16 states anchoring the major US life-sciences clusters.

  • End-of-day SLA

    Coverage review requests come back the same business day. MSA reads are typically half an hour or less.

  • Decoder + glossary

    Free MSA Decoder, 49-clause glossary, 60+ Q&A library. Designed for CFOs, GCs, and Quality leaders.

Free coverage review

A specialist will reach out by end of business day.

Send your contract, sponsor insurance schedule, GPO supplier agreement, hospital purchase contract, or your current COI - whatever you have. A specialist returns a clause-by-clause review within one business day.

Get my coverage review

A specialist will reach out by end of business day.